

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

**LUKASHEV et al.**

Application No.: 12/526,296 (abandoned)

§ 371(c) Date: January 13, 2011

For: Treatment for Multiple Sclerosis

)  
 )  
 ) Group Art Unit: 1649  
 )  
 ) Examiner: Ulm, John D. (during pendency)  
 )  
 ) Confirmation No.: 5197  
 )  
 )  
 )

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Commissioner:

**AMENDMENT TO SPECIFICATION**

Further to Biogen’s Miscellaneous Motion 1 (Requesting Entry of ADS and/or  
 Amendment in Biogen Priority Application No. 12/526,296) filed in Patent Interference No.  
 106,023, Patentee respectfully requests that the specification be amended as shown below.

**AMENDMENT TO THE SPECIFICATION:**

Please amend the specification as follows:

On page 1, below the title of the application, please add the following new paragraph:

**CROSS REFERENCE TO RELATED APPLICATIONS**

This application is the U.S. National Phase of International Application No. PCT/US2008/001602, filed February 7, 2008, which claims the benefit of U.S. Provisional Application 60/888,921, filed February 8, 2007.

**REMARKS**

Further to Biogen's the Miscellaneous Motion 1 identified above and for the reasons set forth therein, Patentee respectfully requests entry of this amendment.

Please charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: July 20, 2015

By: /Michele C. Bosch/  
Michele C. Bosch  
Reg. No. 40,524  
(202) 408-4000